Nostrum Labs Issues nationwide Recall of Sucralfate Tablets Due to Quality Concerns

Nostrum Labs has initiated a voluntary nationwide recall of all Sucralfate Tablets USP lots that are currently within their expiration date and were manufactured after June 2023. the company has stated that they can no longer guarantee that these tablets will meet their intended specifications for the remainder of their shelf life.

This recall is a result of Nostrum Labs’ discontinuation of its quality program, which means the company cannot assure that the product adheres to its established identity, strength, quality, and purity characteristics. While no specific risks to patients from using an adulterated product have been identified, the company emphasized that such risks cannot be ruled out.

The affected Sucralfate Tablets USP were distributed to a wide range of entities, including wholesalers, retailers, manufacturers, medical facilities, and repackagers. No other Nostrum Labs products are impacted by this recall.

The company stressed that all recalled lots of Sucralfate Tablets USP should be destroyed promptly and that they are not accepting returns.

To date, Nostrum Labs has reported no adverse events associated with this recall. the company is actively notifying all parties who received the affected product via email and US mail. these recipients are urged to inform their subsidiaries, receiving sites, customers, retailers, and consumers about the recall.

Individuals with questions regarding the recall can contact Nostrum Labs at [email protected].

patients experiencing any issues that might potentially be related to the recalled Sucralfate Tablets USP should notify their veterinarians or healthcare providers.Any adverse effects or quality issues can be reported to the FDA’s MedWatch Adverse Event reporting program. Reporting can be done via mail, fax, or online through www.fda.gov/medwatch/report.htm. Forms for mail or fax reporting can be downloaded from www.fda.gov/medwatch/getforms.htm or requested by calling 1-800-332-1088.

What are the potential risks associated with off-label medication use, as highlighted by this recall?

Recall of Off-Label Ulcer Medication Triggers Investigation

What is an Off-Label Prescription?

The recent recall of[MedicationName-[MedicationName-replace with actual medication name], a proton pump inhibitor (PPI) commonly used for acid reflux and gastroesophageal reflux disease (GERD), has sparked a significant investigation. the core of the issue revolves around its off-label use for treating peptic ulcers – specifically, ulcers resistant to standard treatments. Off-label prescription means a medication approved by regulatory bodies like the FDA for one condition is being used to treat another. While legal and sometimes medically necessary, it carries increased scrutiny and potential risk.

FDA Approval: Medications undergo rigorous testing for specific indications.

Physician Discretion: Doctors can legally prescribe approved drugs for unapproved uses if they believe it’s medically appropriate.

Increased Monitoring: Off-label use requires careful patient monitoring due to limited data on efficacy and safety for the new indication.

The recall, initiated on July 22, 2025, by[ManufacturingCompanyName-[ManufacturingCompanyName-replace with actual company name], affects multiple lot numbers of the medication. The primary concern stems from reports of unexpected adverse reactions in patients using the drug off-label for ulcer treatment. These reactions include:

Severe Allergic Reactions: Including anaphylaxis and angioedema.

Cardiac Arrhythmias: Irregular heartbeats reported in a small percentage of patients.

Kidney Dysfunction: Cases of acute kidney injury have been linked to the medication.

Patients who have been prescribed [Medication name] for ulcer treatment,particularly those with pre-existing heart or kidney conditions,are urged to contact their healthcare provider immediately. A complete list of recalled lot numbers can be found on the FDA website ([linktoFDArecallpage-[linktoFDArecallpage-replace with actual link]).

Investigation Focus: manufacturing & Data Clarity

The investigation, led by the FDA and supported by the Centers for Disease Control and Prevention (CDC), is focusing on two key areas:

1. Manufacturing Processes: A thorough review of the manufacturing process at [Manufacturing Company Name]’s facilities is underway to identify potential contamination or quality control issues.This includes examining raw material sourcing,production protocols,and final product testing.
2. Data Transparency & Reporting: The FDA is scrutinizing the company’s reporting of adverse events. Concerns have been raised about potential delays in reporting and a lack of transparency regarding the full extent of the adverse reaction data. This is crucial for understanding the true risk profile of the medication, especially when used off-label.

Understanding the Risks of Off-Label PPI Use for Ulcers

While PPIs are effective for reducing stomach acid, their off-label use for complex ulcers presents unique challenges.

Drug Interactions: Ulcer patients frequently enough take multiple medications, increasing the risk of potentially dangerous drug interactions.

long-Term Effects: prolonged PPI use, even for approved indications, has been linked to nutrient deficiencies (Vitamin B12, magnesium), bone fractures, and an increased risk of Clostridium difficile infection.These risks may be amplified with off-label use.

Helicobacter pylori: Manny ulcers are caused by Helicobacter pylori infection. Effective treatment requires eradication of the bacteria, often with antibiotics in addition to acid suppression. Relying solely on a PPI without addressing the underlying infection can lead to treatment failure and prolonged symptoms.

Contact Your Doctor: Schedule an appointment to discuss your situation and explore choice treatment options.

Report Adverse Reactions: Report any suspected adverse reactions to the FDA’s MedWatch program ([linktoMedWatch-[linktoMedWatch-replace with actual link]).

Review Your Medication List: Ensure your doctor is aware of all medications and supplements you are taking.

seek Second Opinion: If you are unsure about your treatment plan, consider seeking a second opinion from a gastroenterologist.

This recall underscores the importance of robust pharmacovigilance – the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. Effective pharmacovigilance relies on:

Spontaneous Reporting Systems: Like the FDA’s MedWatch.

Clinical Trial Data: Ongoing monitoring of drug safety during clinical trials.

Post-Market Surveillance: Continuous monitoring of drug safety